Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (4561)	1/11/2006 4:09:32 PM
From: sjemmeri	Read Replies (2) \| Respond to of 4974

1/11/2006 ALTU Biotech Altus Pharmaceuticals files terms Altus Pharmaceuticals, a developer of oral and injectable protein therapeutics for chronic gastrointestinal and metabolic disorders, announced Wednesday that it will offer 6.0 million shares at a range of $14 to $16. Assuming the stock prices at the midpoint, the company will have an initial market capitalization of $300 million. Merrill Lynch and Morgan Stanley are the joint book runners on the deal. Timing has yet to be determined.